Items where authors include "Katona, E."

Article

Kempthorne, L., Vaizoglu, D., Cammack, A.J. et al. (27 more authors) (2025) Dual-targeting CRISPR-CasRx reduces C9orf72 ALS/FTD sense and antisense repeat RNAs in vitro and in vivo. Nature Communications, 16 (1). 459. ISSN 2041-1723

Vasudev, N.S. orcid.org/0000-0001-8470-7481, Ainsworth, G., Brown, S. et al. (24 more authors) (2023) Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM). Journal of Clinical Oncology. ISSN 0732-183X

Vasudev, N.S. orcid.org/0000-0001-8470-7481, Ainsworth, G. orcid.org/0000-0002-9952-8440, Brown, S. orcid.org/0000-0002-7975-7537 et al. (24 more authors) (2023) Standard versus modified ipilimumab, in combination with nivolumab, in advanced renal cell carcinoma: a randomized phase II trial (PRISM). Journal of Clinical Oncology. JCO2300236. ISSN 0732-183X

Horne, A., Brown, S., Butterworth, K. et al. (26 more authors) (2022) EP05.01-007 CONCORDE - A Phase Ib Platform Study of Novel Agents in COmbinatioN with COnventional RaDiothErapy in Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 17 (9). s267-s268. ISSN 1556-0864

Krajnik, M., Hepgul, N., Wilcock, A. et al. (59 more authors) (2022) Do guidelines influence breathlessness management in advanced lung diseases? A multinational survey of respiratory medicine and palliative care physicians. BMC Pulmonary Medicine, 22. 41. ISSN 1471-2466

Coen, O., Corrie, P., Marshall, H. et al. (17 more authors) (2021) The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. BMC Cancer, 21 (1). 761. ISSN 1471-2407

Menegatti, M., Palla, R., Boscarino, M. et al. (6 more authors) (2017) Minimal factor XIII activity level to prevent major spontaneous bleeds. Journal Of Thrombosis And Haemostasis, 15 (9). pp. 1728-1736. ISSN 1538-7933

Proceedings Paper

Danson, S., Collinson, M., Plummer, E.R. et al. (17 more authors) (2025) Comparison of 1 year versus minimum 2 years of anti-PD1-based immunotherapy as first-line treatment for metastatic melanoma: Results of the DANTE phase III trial. In: Journal of Clinical Oncology. 2025 ASCO Annual Meeting II, 30 May - 03 Jun 2025, Chicago, USA. American Society of Clinical Oncology (ASCO) .